Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer

Clinical Cancer Research

Volumn 10, Issue 15, 2004, Pages 5038-5047

  Tan, Antoinette R ^a   Yang, Xiaowei ^a   Berman, Arlene ^a   Zhai, Suoping ^a   Sparreboom, Alex ^a   Parr, Allyson L ^a   Chow, Catherine ^c   Brahim, Jaime S ^d   Steinberg, Seth M ^b   Figg, William D ^a   Swain, Sandra M ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DOCETAXEL; FLAVOPIRIDOL; KI 67 ANTIGEN; PHOSPHOPROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CHEEK MUCOSA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; FATIGUE; FEASIBILITY STUDY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEMICOLECTOMY; HUMAN; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; ILEOSTOMY; IMMUNOHISTOCHEMISTRY; ISCHEMIC COLITIS; METASTASIS; MYALGIA; NAUSEA; NEUTROPENIA; ORAL BIOPSY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STEADY STATE; THROMBOCYTOPENIA; TYPHOID FEVER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BIOPSY; BREAST NEOPLASMS; CLINICAL TRIALS; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; FEMALE; FLAVONOIDS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; MOUTH MUCOSA; MUCOUS MEMBRANE; NEOPLASM METASTASIS; PHOSPHORYLATION; PIPERIDINES; RETINOBLASTOMA PROTEIN; TAXOIDS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4143122204     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0025     Document Type: Article

References (39)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Giordano A, Rustum YM, Wenner CE. Cell cycle: molecular targets for diagnosis and therapy: tumor suppressor genes and cell cycle progression in cancer. J Cell Biochem 1998;70:1-7.
3. Dickson C, Fantl V, Gillett C, et al. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett 1995;90:43-50.
4. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994;57:353-61.
5. Kaur G, Stetler-Stevenson M, Sebers S, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst (Bethesda) 1992;84:1736-40.
6. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56:2973-8.
7. Parker BW, Kaur G, Nieves-Neira W, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998;91:458-65.
8. Schrump DS, Matthews W, Chen GA, Mixon A, Altorki NK. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin Cancer Res 1998;4:2885-90.
9. Brusselbach S, Nettelbeck DM, Sedlacek HH, Muller R. Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells. Int J Cancer 1998;77:146-52.
10. Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L, Senderowicz AM. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 1999;59:5433-7.
11. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 1997;57:3375-80.
12. Carlson B, Lahusen T, Singh S, et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1999;59:4634-41.
13. Li Y, Bhuiyan M, Alhasan S, Senderowicz AM, Sarkar FH. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol. Clin Cancer Res 2000;6:223-9.
14. Bible KC, Bible RH Jr, Kottke TJ, et al. Flavopiridol binds to duplex DNA. Cancer Res 2000;60:2419-28.
15. Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999;5:1876-83.
16. Motwani M, Li XK, Schwartz GK. Docetaxel and navelbine induced apoptosis is enhanced by flavopiridol in breast cancer cells and is sequence dependent [Abstract]. Proc Am Assoc Cancer Res 2000;41:143.
17. Motwani M, Rizzo C, Sirotnak F, She Y, Schwartz GK. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2003;2:549-55.
18. Schwartz GK, O'Reilly E, Ilson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002;20:2157-70.
19. Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998;16:2986-99.
20. Tan AR, Headlee D, Messmann R, et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 2002;20:4074-82.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (Bethesda) 2000;92:205-16.
22. Baker SD, Zhao M, He P, Carducci MA, Verweij J, Sparreboom A. Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. Anal Biochem 2004;324:276-84.
23. Zhai S, Sausville E, Figg WD. A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma. Biomed Chromatogr 2002;16:379-82.
24. Rudek MA, Bauer KS Jr, Lush RM III, et al. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother 2003;37:1369-74.
25. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114.
26. Stadler WM, Vogelzang NJ, Amato R, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago phase II consortium study. J Clin Oncol 2000;18:371-75.
27. Schwartz GK, Ilson D, Saltz L, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001;19:1985-92.
28. Shapiro GI, Supko JG, Patterson A, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001;7:1590-9.
29. Patel B, El-Rayes F, Gadgeel SM, Lorusso P, Philip PA. A phase I study of flavopiridol and docetaxel [Abstract]. Proc Am Soc Clin Oncol 2003;22:233.
30. Kasimis B, Rocha-Lima C, Cogswell J, Mahany JJ, Rodriguez L, Gries JM. Phase I study evaluating 1-hour flavopiridol (HMR1275) in combination with docetaxel in previously treated non-small cell lung cancer patients [Abstract]. Proc Am Soc Clin Oncol 2003;22:669.
31. Thomas JP, Tutsch KD, Cleary JF, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002;50:465-72.
32. Ljungman M, Paulsen MT. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol Pharmacol 2001;60:785-9.
33. Lam LT, Pickeral OK, Peng AC, et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001;2:1-11.
34. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.
35. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003;3:233-45.
36. Geng Y, Yu Q, Sicinska E, et al. Cyclin E ablation in the mouse. Cell 2003;114:431-43.
37. Grant S, Roberts JD. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resist Upd 2003;6:15-26.
38. Nahta R, Iglehart JD, Kempkes B, Schmidt EV. Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res 2002;62:2267-71.
39. Yu C, Krystal G, Dent P, Grant S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res 2002;8:2976-84.